Breadcrumb

PRESS RELEASES

PRESS RELEASES

DateTitle 
11/14/19
- Exicure to Receive $25 Million Upfront Payment and Up to $725 Million in potential Milestones - Exicure to Host Conference Call Today at 8:30am ET / 7:30am CT CHICAGO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 14, 2019-- Exicure, Inc. , (NASDAQ:XCUR) a pioneer in gene regulatory and
11/13/19
CHICAGO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 13, 2019-- Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that David Giljohann , chief executive officer Exicure, Inc.
11/07/19
CHICAGO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 7, 2019-- Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported financial results for the third quarter ended September 30, 2019 and provided an
10/21/19
CHICAGO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 21, 2019-- Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its chief financial officer, David Snyder , will give a company update on
10/16/19
-- XCUR17 clinical results announced in presentation at the 15 th Annual Meeting of the Oligonucleotide Therapeutics Society in Munich -- -- Clinical results presented show decrease in the levels of psoriasis and inflammation markers -- CHICAGO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct.
10/14/19
CHICAGO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 14, 2019-- Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its CEO, David Giljohann , PhD, will present clinical data from the company’s
09/17/19
CHICAGO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 17, 2019-- Exicure, Inc . (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its chief operating officer, Dr.
09/03/19
CHICAGO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 3, 2019-- Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced presentations at the following investor conferences during the months of September
08/08/19
CHICAGO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 8, 2019-- Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today reported financial results for the second quarter ended June 30, 2019 and provided an update
08/07/19
CHICAGO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 7, 2019-- Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced the appointment of Dr. Bali Muralidhar, a partner at Abingworth LLP , and Mr.
08/02/19
CHICAGO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 2, 2019-- Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced the closing of its previously announced underwritten public offering of 31,625,000
07/31/19
CHICAGO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 31, 2019-- Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced that its common stock will begin trading on the Nasdaq Capital Market under the
07/30/19
CHICAGO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 30, 2019-- Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that it intends to offer and sell shares of its common stock in an underwritten
07/22/19
CHICAGO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 22, 2019-- Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced its appointment of Jeffrey L. Cleland , Ph.D. and Timothy P.
07/11/19
CHICAGO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 11, 2019-- Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, is proud to announce Co-founder Chad A. Mirkin has been awarded the $250,000 Kabiller Prize in
06/26/19
CHICAGO & CAMBRIDGE, Mass.--( BUSINESS WIRE )--Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced data from a preclinical study evaluating the biodistribution of SNAs in the non-human primate
06/03/19
CHICAGO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 3, 2019-- Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its CFO, David Snyder , will give a company presentation on Tuesday, June
05/22/19
CHICAGO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 22, 2019-- Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced a presentation at TIDES: Oligonucleotide and Peptide Therapeutics, the world’s largest
05/09/19
CHICAGO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 9, 2019-- Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced a poster presentation at the Society for Investigative Dermatology (SID) Meeting , May
05/08/19
CHICAGO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 8, 2019-- Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today reported financial results for the first quarter ended March 31, 2019 and provided an update on
05/03/19
SKOKIE, Ill. --(BUSINESS WIRE)--May 3, 2019-- Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced a poster presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia,
04/30/19
SKOKIE, Ill. --(BUSINESS WIRE)--Apr. 30, 2019-- Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced a poster presentation at ARVO 2019 Annual Meeting in Vancouver, British Columbia .
04/01/19
SKOKIE, Ill. --(BUSINESS WIRE)--Apr. 1, 2019-- Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its CEO, Dr. David Giljohann , will give a company presentation on Monday, April 8, 2019 at
04/01/19
Two posters are being presented at the AACR Annual Meeting in Atlanta, Georgia Exicure’s TLR9 agonist shows activation of NK cells and T cells in a Phase 1 clinical trial Data presented in collaboration with Celldex show that Exicure’s technology leads to a more potent anti-tumor response when
03/26/19
SKOKIE, Ill. --(BUSINESS WIRE)--Mar. 26, 2019-- Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its CFO, David Snyder , will give a company presentation on Tuesday, April 2, 2019 at 9:30
03/08/19
Completed Phase 1 clinical trials of two drugs and began public trading SKOKIE, Ill. --(BUSINESS WIRE)--Mar. 8, 2019-- Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today reported full year financial results
02/25/19
SKOKIE, Ill. --(BUSINESS WIRE)--Feb. 25, 2019-- Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that it has dosed the first patient in its multicenter, open-label, Phase 1b/2 study
02/21/19
SKOKIE, Ill. --(BUSINESS WIRE)--Feb. 21, 2019-- Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its CEO, Dr. David Giljohann , will present a corporate update at the 12 th Annual
02/19/19
– Agreement Leverages Recent Clinical Success of Exicure in Dermatology – SKOKIE, Ill. & NEW YORK --(BUSINESS WIRE)--Feb. 19, 2019-- Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, and Dermelix
02/18/19
SKOKIE, Ill. --(BUSINESS WIRE)--Feb. 18, 2019-- Exicure, Inc. (OTCQB:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its CEO, Dr. David Giljohann , will present at SMi’s RNA Therapeutics 2019 Conference being
02/06/19
SKOKIE, Ill. --(BUSINESS WIRE)--Feb. 6, 2019-- Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its CEO, Dr. David Giljohann , will present a corporate update on Monday, February 11, 2019
02/05/19
SKOKIE, Ill. --(BUSINESS WIRE)--Feb. 5, 2019-- Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced four of the clinical trial sites for the Company’s Phase 1b/2 trial of AST-008.
02/04/19
SKOKIE, Ill. --(BUSINESS WIRE)--Feb. 4, 2019-- Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that its CEO, Dr. David Giljohann , will present at the Immuno-Oncology 360° Conference (IO360°)
01/03/19
SKOKIE, Ill. --(BUSINESS WIRE)--Jan. 3, 2019-- Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional spherical nucleic acid (SNA™) constructs, announced today that its CEO, Dr. David Giljohann , will present a corporate update on

Print Page  | RSS Feeds  | E-mail Alerts  | IR Contacts